Thanks G13
Last ann re world-famous Dr Rotstein appointment is for Nasdaq purpose.
Yacov can always issue minimal number of shares (ADR) for initial Nasdaq x-listing purpose.
When in future , sp has shot up and the time is right, he can always issue more at much higher price
Nasdaq cross listing main purpose is exposure to more sophiscated investors in usa; they have more eyes for unique techco, less interest in miners.
Yes, at A$110m ( SOI 281m x 29c)
Gmv is undervalued based on fwd U$22m (A$31, POs, Hugea + Cyprus), plus IDTFs (U$5-6 m, excl Primza or GMP subscribers)
plus few more,POs in forseebale future.
10x to 15x to 20x revenue, wold be gr8!
A$310m to A$620m , vs $110m today.
Having waited for months, another few weeks are bearable;i can only speak for meself.
We have commercial med-devices ready for a mkt of 200m-300m patients; not R&D concepts.
aimo
- Forums
- ASX - By Stock
- GMV
- Nasdaq?
Nasdaq?, page-52
-
- There are more pages in this discussion • 101 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)